EP1212083A1 - Vaccins oraux a base de lactobacilles recombinees - Google Patents

Vaccins oraux a base de lactobacilles recombinees

Info

Publication number
EP1212083A1
EP1212083A1 EP00962689A EP00962689A EP1212083A1 EP 1212083 A1 EP1212083 A1 EP 1212083A1 EP 00962689 A EP00962689 A EP 00962689A EP 00962689 A EP00962689 A EP 00962689A EP 1212083 A1 EP1212083 A1 EP 1212083A1
Authority
EP
European Patent Office
Prior art keywords
plantarum
antigen
vaccine
lactobacillus
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00962689A
Other languages
German (de)
English (en)
Inventor
David Michael Shaw
Robert Jan Leer
Peter Pouwels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority to EP00962689A priority Critical patent/EP1212083A1/fr
Publication of EP1212083A1 publication Critical patent/EP1212083A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the subject invention lies in the field of vaccine development. Specifically the invention is concerned with the development of oral vaccines.
  • the invention involves the use of recombinant non pathogenic bacteria as carriers of an antigen capable of eliciting immune response after oral application. More specifically the invention covers the use of a lactic acid bacterium of the genus Lactobacillus.
  • the lactic acid bacterium concerned is classified as a Lactobacillus plantarum.
  • the antigen is expressed intracellularly and/or exposed on the surface of the Lactobacillus.
  • the vaccine is a live vaccine in that it uses live microorganisms as carrier of the antigen.
  • the invention also covers new recombinant Lactobacillus plantarum and expression vectors for use therein.
  • Mucosal vaccines i.e. vaccines using the mucosal delivery route appear to offer several advantages over systemic inoculation. They can be used to generate an IgA based immune response as a first line of defence. The protective immune response to mucosal infections is strongly dependent on the production of secretory IgA molecules. Such molecules are produced locally and are transported to the mucosal secretion products.
  • mucosal vaccines Another category of mucosal vaccines that could be useful aims at systemic immune response induction via mucosal application of the vaccine rather than parenteral application. Ideally the immune response should be equal to that of parenteral vaccines to be sufficiently effective.
  • lactic acid bacteria has seemed a suitable starting point when looking for a group of harmless microorganisms to be used as antigen carriers. They are used on a large scale use in the food production technology. They form a group of food grade (i.e. usually with GRAS-status) gram positive microorganisms suitable for human consumption. They have a long record of safe use in food products. An additional interesting aspect in their favour is of course the absence of LPS (which appear in some pathogenic microorganisms currently used as carriers). Thus as no problems with endotoxic shock risks would be anticipated they are apparently safe to apply via the mucosal route. In addition, lactic acid bacteria are produced as probiotics due to the colonising, i.e. capable of settling and or growing, of cavities such as mouth, urogenital or gastrointestinal tracts, where they play a role in maintaining a balanced normal microflora. To date however no oral vaccine using non pathogenic bacteria is commercially available.
  • Lactobacillus plantarum strains as or in nasal vaccines have been described and both are equally suitable for this route of administration. Surprisingly, in the present invention, it has been found that Lactobacillus plantarum strains are suitable for use as or in an oral vaccine. In contrast - as further discussed below - the art has not been able to obtain comparable results with other Lactobacillus strains, such as L .casei, that have been suggested as nasal vaccines (Pouwels et al., J. Biotech. 1996 44:183- 192; Pouwels et al., Int. J. Food Microbiol. 1998 41 :155-167).
  • the third category is that of the Lactobacillus based vaccines and includes nasally introduced recombinant Lactobacilli capable of inducing immune response. However as yet there is no orally introduced recombinant Lactobacilli that has actually induced an immune response. Instead there are speculative disclosures of recombinant non pathogenic bacteria expressing heterologous antigens in vivo for producing a significant immune response upon oral application of the bacterium.
  • One study discloses an unsuccessful experiment involving oral introduction into mice of a recombinant Lactobacillus expressing a heterologous antigen intracellularly (Wells et al., Antonie van Leeuwenhoek 1996 70:317-330).
  • Lactobacillus plantarum 80 expressing E. coli ⁇ -galactosidase intracellularly, was introduced orally into mice on days 0,1 and 2. Subsequent oral boosting occurred after a 4 week interval. This experiment revealed no significant antibody responses to the ⁇ - galactosidase (the heterologous antigen), a protein not known for any immunogenic properties. This result was in contrast to intraperitoneal results where an immune reaction was achieved, using the same bacterial strain, the same antigen and the same expression system. Numerous explanations for this failure can be put forward, but none of so far have clarified the lack of good results for oral vaccination.
  • the suggested bacteria are Lactobacillus delbruekii, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus coryniformis, Lactobacillus brevis, Lactobacillus leichmannii and strains of Lactobacillus isolated from intestinal flora such as Lactobacillus rhamnosus 901.
  • the latter is indicated as being especially preferred as it possesses resistance both to acid and bile juices.
  • the lactic acid bacterium mentioned in the Examples is Lactobacillus plantarum 8826 (3x10 9 bacteria/ml, twice a day for 18 days).
  • the lactic acid bacteria according to WO99/11284 should produce urease as heterologous antigen. No other antigen is suggested and illustration of successful induction of an immune response in vivo is provided. The example supposedly illustrating this is merely speculative in nature and no actual results are provided. Also it suggests that the antigen (urease) was excreted by the bacterial host into its surroundings as a "free", soluble protein ( i.e. not exposed on or otherwise associated with the surface of the bacterial host). There are in fact serious doubts as to whether the postulated method would be successful in providing an immune reaction.
  • the review article (Mercenier of 1999) describes numerous constructs expressing heterologous antigens (e.g. TTFC) that have been introduced into Lactobacillus plantarum NCIMB 8826 (a human saliva isolate). For all these recombinant Lactobacilli constructs nasal introduction in mice resulted in an immune response. In addition it indicates that oral tests have also been carried out for comparison but no results for the oral experiments are presented and there is no mention of where in the cell the antigens are expressed. Thus there is also no mention of whether any, some or all of the constructs produced any significant immune reaction.
  • heterologous antigens e.g. TTFC
  • Lactobacillus casei was an example of a useful host.
  • previous experiments have compared recombinant L. plantarum and non recombinant L. casei for eliciting adjuvant activity.
  • L. casei was shown to be the best microorganism eliciting in vivo adjuvant activity.
  • L. casei would be the preferred candidate for a vaccine over L. plantarum or any other strain of lactic acid bacteria.
  • a first aspect of the invention is an (e.g. oral) vaccine comprising a recombinant lactic acid bacterium expressing a heterologous antigen (suitably in vivo).
  • the antigen can be expressed intracellularly and/or (exposed) on the surface of the lactic acid bacterium. This can thus be a specific immunogenicity eliciting component for eliciting immunogenicity against the heterologous antigen, or can elicit an (immune) response.
  • the recombinant lactic acid bacterium is preferably a Lactobacillus organism, such as L. plantarum, and optionally at least one pharmaceutically acceptable carrier suitable for use in a formulation for oral delivery is present.
  • Bacterial host means the bacterium or bacterial strain that is used to express the desired antigen(e.g. via recombinant techniques). This is administered to a human or animal (mammal) in or as part of a vaccine in order to illicit an immune response against the antigen.
  • the term is used to designate the native strain transformed to express the antigen, the recombinant strain expressing the antigen (also referred to separately as “recombinant host strain”), or both.
  • “Mucosal delivery (route)" of a vaccine means any route of administration to the body of a human or animal for which it is not required to penetrate or puncture the skin (e.g. as with intravenous, intramuscular, subcutaneous or intraperitoneal administration). Usually, this means that the vaccine is administered to the body via one of the body cavities, such that it comes into contact with the mucosa. Hence mucosal administration in particular refers to nasal, oral and/or vaginal administration.
  • “Mucosal vaccine” means any vaccine suited, adapted, intended and/or formulated for mucosal delivery.
  • Oral delivery (route) (of a vaccine) means any route of delivery to the body of a human or animal into, by which the vaccine can be presented to, the gastrointestinal (G.I.) tract or any part thereof. Usually, this will involve administration into or via the mouth into the G.I. tract. "Oral administration” also includes administration directly into the G.I. tract or into any part thereof, and including into the stomach, for instance using a tube or catheter.
  • Oral vaccine means any vaccine suited, adapted, intended and/or formulated for oral delivery as defined above.
  • a response (e.g. an antibody response or immune response) is deemed “significant” if it leads to a detectable change or response in a human or animal, and in particular to a detectable immunological change or response, such as the production of antibodies, cytokines, lymphokines, etc.
  • Tests for determining whether a response is "significant” are known in the art and include, but are not limited to, titration of antibody levels in biological samples using ELISA techniques, ELISPOT techniques and in vitro lymphocyte stimulation assays. Such techniques are usually carried out on a biological sample, such as a biological fluid or cell sample, obtained from the human or animal.
  • a "significant” response may be, but is not necessarily, also a “protective” response as defined below.
  • a response (e.g. an immunological response against a pathogen or an antigen) is deemed “protective” when it is capable of protecting the human or animal having the response against the pathogen and/or against a pathogen associated with the antigen.
  • An antigen is deemed “exposed” on a bacterial host (also be referred to as "(surface) exposition” of the antigen) when it is present, forms part of, is attached to, and/or is otherwise associated with or detectable on (e.g. using a suitable immunological detection technique such as FACS or immunofluorescent microscopy) the surface of the bacterial host (e.g. the bacterial cell wall or envelope)
  • a suitable immunological detection technique such as FACS or immunofluorescent microscopy
  • "exposed" means that the bacterium - when presented to a cell of a human or animal that is capable of mediating an immune response (such as the cells of the G.I. tract mentioned below) for a sufficient time and in a sufficient amount - is capable of eliciting a "sufficient" immune response against the antigen.
  • an immune response such as the cells of the G.I. tract mentioned below
  • a Lactobacillus plantarum strain can readily be determined using known parameters (e.g. Bergeys Manual of determinative bacteriology and Vescovo et al, Ann. Microbiol. Enzymol. 43 261-284 (1993)). The skilled person can therefore readily determine whether a lactic acid bacterium is a Lactobacillus plantarum. Numerous Lactobacillus plantarum strains have been deposited at various institutes and are readily available.
  • the native strain selected as the bacterial host should preferably have GRAS (generally regarded as safe) status, and more preferably be food grade.
  • GRAS generally regarded as safe
  • the bacterial host used should allow - upon transformation with an appropriate construct encoding an antigen- expression of the desired antigen either intracellularly and/or exposed on the surface.
  • the level of expression of the antigen - e.g. intracellulary and/or exposed on the surface as determined by SDS-polyacrylamide gel electrophoresis or FACS should be at least from 1-5 % of the total cell protein, or alternatively 80% or more, preferably 100% or more, of the level of expression provided by L. plantarum strain 256 under the same conditions and using the same expression vector.
  • the bacterial host is preferably capable of settling in and/or colonizing at least part of the gastrointestinal tract, such as the mouth, the throat, the larynx, the gut, the small intestine, the large intestine, the ileum and/or the colon, or a combination thereof.
  • the bacterial host is such that it mainly settles in the intestine, more preferably in the small intestine or caecum.
  • the (recombinant) Lactobacillus plantarum strain preferably exhibits a persistance in the individual to be immunized (upon oral administration and as determined by the presence of the strain in the faeces) of at least 5 days, preferably at least 9 days, and suitably more than 15 or even 20 days. Longer persistance may not be required if an administration regimen comprising the use of one or more booster immunisations as described below.
  • a preferred embodiment exhibits a persistance longer than that of L. plantarum
  • L. plantarum strain 80 is not LMG 9211 (NCIMB 8826 as described by Mercinier above), DSM 4229 L. casei 393, and/or L. plantarum 80.
  • the bacterial host is one of the following L.
  • plantarum strains 256, LMG 1284, LMG 6907, LMG 8155, LMG 9205, LMG 9206, LMG 9208, LMG 9209, LMG 9210, LMG 9212, LMG 11405, LMG 11460, LMG 8095, LMG 8027, LMG 12167, LMG 13556, LMG 17552, LMG 18021, LMG 18023, LMG 18024, LMG 18027, LMG 18095; 386, 299 , 105 or 275 (see Molin et al, 1993. J. Appl. Bacteriol. 74:314), 299v (see Molin et al, 1993. J. Appl. Bacteriol. 74:314), 299v (see Molin et al, 1993. J. Appl. Bacteriol. 74:314), 299v (see Molin et al, 1993. J. Appl. Bacteriol. 74:314), 299v (see WO 96/29083);
  • the Lactobacillus bacterium employed is foreign to the individual (human or animal) to which it is to be administered, for example vaccinated.
  • the bacteria of the invention are modified or recombinant, and it is so the wild-type or naturally occurring bacteria, that is to say the non-recombinant or unmodified Lactobacillus, that is suitably foreign.
  • foreign it is intended to refer to a Lactobacillus strain that the individual (or humans) has not encountered before.
  • the strain will be one not found in humans or animals, for example a strain that does not exist in the gut (G.I. tract).
  • the present invention therefore preferably uses a Lactobacillus strain that is not found in the mucosa (non-mucosal) or G.I. tract of individual, for example it is not endogenous (to humans or a species of animal to be vaccinated). Indeed, the most preferred strains (e.g. L. plantarum 256) are found in silage. Such strains are clearly foreign to humans, and so provide an increased immune response. Nevertheless, preferably the strain may be capable of adhering to the intestinal mucosa.
  • a Lactobacillus strain that is not found in the mucosa (non-mucosal) or G.I. tract of individual, for example it is not endogenous (to humans or a species of animal to be vaccinated). Indeed, the most preferred strains (e.g. L. plantarum 256) are found in silage. Such strains are clearly foreign to humans, and so provide an increased immune response. Nevertheless, preferably the strain may be capable of adhering to
  • the strain may also be of non-foodstuff origin, for example not found in (human) foods. This may thus exclude some L. casei strains, e.g. 393. Strain 393 is found in cheese, and so preferably strains found in dairy or fermentation products are excluded. This means that the individual has not (or may not) have had contact (e.g. ingested) the strain, and so using strains not found in foods is more likely to provoke an immune response. This may explain the long persistence times found with certain Lactobacilli. It may be that those bacteria are cleared more slowly as they are not recognised by the immune system. Suitably the strain is thus of animal origin, for example from an animal feedstuff (e.g. silage). Strains that are generally more suitable are commensal (in the gut), rather than dietary (e.g. dairy origin).
  • the Lactobacillus strain is viable (or alive) and intact. Suitably they will be able to persist (in the mucosa) of the individual for at least 7 days. This can easily be tested using procedures known in the art (for example, testing for the existence of the organism in faeces).
  • the invention additionally relates to a non-human and/or non-human food Lactobacillus bacterium, such as L. plantarum, which has been modified to express a heterologous antigen (intracellularly and/or on the cell surface).
  • This bacterium is preferably able to elicit an immune response in an individual, to whom the bacterium is administered.
  • the naturally occurring or unmodified L. plantarum is preferably foreign to that individual, for example it is not endogenous to humans or the animal to which it is to be administered.
  • the chosen L. plantarum strain will not be present in the G.I. tract or mucosa of humans or that species of animal.
  • the invention also relates to an L. plantarum bacterium which has been modified to express an heterologous antigen intracellularly and/or on the cell surface, to elicit immune response to an individual and which can persist in the gastrointestinal tract of that individual for at least 7 days.
  • biochemical properties of the strain used for example its sugar fermentation profile (API), cell wall composition, structure of LTA, structure of peptidoglycan, 16S RNA sequence, acid resistance, bile acid resistance, agglutination properties, adjuvanticity, immune modulating properties, in vitro adherence properties, mannose-specific adherence, presence of proteinaceous adherence factors, presence of mapA-like adherence factors and/or presence of large proteinaceous adherence factors with repeated amino acid sequences; and/or
  • API sugar fermentation profile
  • the interaction of the bacterial host with cells of the individual to which the host to be administered i.e. as part of a vaccine according to the invention
  • the host to be administered including but not limited to its persistence , viability, in vivo expression of antigen and/or tissue-specific persistence.
  • the strain used should be essentially (at least) equivalent to the strains mentioned above, and more preferably equivalent to L. plantarum 256, e.g. as determined on the basis of tests/assays for these properties known er se in the art.
  • a suitable host After a suitable host has been selected, it may be transformed with a genetic construct as described herein, after which its suitability as an oral vaccine may be tested, i.e. using the tests and protocols described in the Examples later. It is envisaged that on the basis of the description herein, and optionally after carrying out - for the purposes of confirmation- the tests described herein, the skilled person will be able to identify other L. plantarum strains suitable for use as or in vaccines of the invention.
  • the L. plantarum is in the group (or cluster) 1 , (which includes strains 101, 97, 53, 256, ATCC 14917, 36 E , 95, 98, 299, 299v, 107, 105, 79, 275, 386, So5 and ATCC 8014), suitably subgroup (or subcluster) lb (which includes 256, ATCC 14917, 36 E , 95 and 98).
  • group (or cluster) 1 which includes strains 101, 97, 53, 256, ATCC 14917, 36 E , 95, 98, 299, 299v, 107, 105, 79, 275, 386, So5 and ATCC 8014
  • subgroup (or subcluster) lb which includes 256, ATCC 14917, 36 E , 95 and 98.
  • Particularly preferred is the L. plantarum strain 256.
  • a preferred embodiment of the invention is a vaccine wherein the recombinant Lactobacillus plantarum comprises an expression vector capable of expressing the heterologous antigen intracellularly and/or such that the heterologous antigen is exposed on the cell surface under conditions present in the gastrointestinal tract.
  • any embodiments of recombinant Lactobacillus plantarum in the form of a vaccine wherein the heterologous antigen is specific for inducing immunogenicity against a pathogenic microorganism are covered by the scope of the invention.
  • the host may express a heterologous antigen specific for mucosa colonising pathogens or pathogens entering the body via the mucosa, specifically via the oral route.
  • the heterologous antigen can be specific for a gastrointestinal tract colonising pathogen.
  • a heterologous antigen specific for tetanus (Clostridium tetanus), such as TTFC, is a particularly suitable candidate.
  • the recombinant bacterial hosts can comprise expression vectors capable of expressing the heterologous antigen intracellularly and/or such that the heterologous antigen is exposed on the cell surface to a degree sufficient to induce protective immunogenicity.
  • the vaccines are formulated such that a single dose is sufficient.
  • a preferred administration regimen comprises one or more "initial" doses or administrations on any of days 1 to 4, followed by one or more booster administrations on any of days 14 to 21 , and optionally one or more further booster administrations on any of days 28 to 25.
  • a single initial administration, followed by a single booster administration, within this time period, will generally be sufficient.
  • a significant immune response was obtained essentially only after the first booster administration. This was despite the fact that at the time of the first booster - i.e. days 14 to 21- the bacterial host (i.e. from the initial administration) was not longer detectable in the faeces of the individual.
  • the invention therefore relates to a method and preparations suited for such an administration and boosting regimen.
  • the invention also relates to a vaccine comprising a recombinant Lactobacillus plantarum (suitably comprising expression vector(s)) capable of expressing the heterologous antigen intracellularly and/or such that the heterologous antigen is exposed on the cell surface to a degree that exceeds either that of the vector disclosed for Lactobacillus plantarum 80 ⁇ -galactosidase expression or of Lactobacillus plantarum 80 expressing a galactosidase.
  • a degree of expression as possible without damaging the viability of the cell or the host to be vaccinated is envisaged. With higher expression, less frequent and lower doses may be required for immunisation purposes.
  • the dosage regime will not only depend on amount of antigen but also on antigen type and the presence or absence of other immunogenicity stimulating factors in the vaccine.
  • a high degree of expression can be achieved by using homologous expression and/or secretion signals on the expression vectors present in the recombinant Lactobacillus plantarum in the vaccine.
  • Suitably expression regulating signals as present in the constructs in the Examples are useful.
  • Other expression signals will be apparent.
  • the expression vector can optimise expression depending on the Lactobacillus strain it is incorporated in.
  • Lactobacillus plantarum comprising expression vectors capable of expression in Lactobacillus casei are covered. This was not expected to be the case, firstly because of the lack of sufficient expression in Lactobacillus casei for vaccine use and secondly due to the unpredictability of expression levels between various lactic acid bacteria.
  • the preferred Lactobacillus plantarum is Lactobacillus plantarum 256 as this strain provided good results, better than Lactobacillus casei under equivalent conditions.
  • the antigen is able to elicit or stimulate an immune response, and so can be any antigen against which an immune response, more specifically a "significant" immune response and/or a "protective” immune response as defined above, can be elicited in an animal (preferably a mammal such as a human).
  • the antigen will usually be associated with a pathogen, disease state and/or disorder of the human or animal to which the vaccine is to be administered.
  • the antigen will be able to interact with one or more (e.g. specific) receptors, for example present on lymphocytes or in antibodies released from them.
  • the antigen can thus be an immunogen. Since the antigen will generally be one that can elicit an immune response, this will usually exclude enzymes (e.g. urease, ⁇ -galactosidase), for example a protein that is present already in the individual. Antigens are thus preferably foreign to that individual.
  • any antigen, antigenic component or epitope known er se that can be expressed in the microbial host can be used.
  • this will be a peptide, a protein, or an antigenic part or fragment thereof, such as an epitope.
  • it may either be a native antigenic peptide or protein (or part, fragment or epitope thereof) or an antigenic analog or mutant thereof, for instance obtained synthetically or using recombinant DNA techniques.
  • Recombinant bacteria and/or bacterial strains, as well as vaccines based thereon, may be provided that can be used to illicit a significant immune response, and preferably a protective immune response, against various antigens.
  • Suitable antigens include:
  • - viral and/or bacterial antigens including those from (e.g. the gpl60 envelope protein of) the HIV virus, a surface glycoprotein (of a Le is hmania parasite), Shiga-like toxin, Shigella lipopolysaccharide antigen, Escherichia coli fimbrial antigen, a CFA antigen (of an enterotoxigenic Escherichia coli strain), anthrax toxin, pertussis toxin, tetanus toxin; - antigens from such pathogens as herpes virus, rubella virus, influenza virus, mumps virus, measles virus, poliomyelitis virus, rotavirus, respiratory syncytial virus, Campylobacter species, Chlamydial organisms, species of the genus Cryptosporidium, cytomegalovirus, human immunodeficiency virus, Actinomyces species, Entamoeba histolytica, arenaviruses, ar
  • Clostridium botulinum species of the genus Candida, Vibrio cholera, Cryptococcus neoformans, EHEC strains of E.coli O157:H7, O26:Hl 1, Ol l l:H8 and O104:H21, ETEC strains of E. coli, strains of E.coli shown to possess enteroinvasiveness (EIEC), EPEC strains of E.coli, EAggEC strains of E.coli., DAEC strains of E.coli, filoviridae, parvo virus, Filar ioidea,
  • Staphylococcus aureus species of the genus Clostridium per fringens, Helicobacter pylori, Caliciviruses, Giacardia lamblia, Neisseria gonorrhoeae, hantaviruses, hepatitis viruses types A, B, C, D, E, Legionellae strains, Mycobacterium leprae, Listeria monocytogenes, species of the genus Clostridium perfringens, Borrelia burgdorferi, Pseudomonas pseudomallei,
  • the allerben is a human allergen, or an allergen provoking an allergic reaction in the type or species of individual to whom the composition is to be administered. It may be a house or insect allergen, such as from dust mite, e.g. Der p 1.
  • antigenic mutants or analogues thereof - obtained synthetically or via recombinant DNA techniques - may be used.
  • a combination of two or more such antigens may be present or expressed. These antigens may be expressed by a single (type or strain) of bacterial host, or by several different (types or strains) of bacterial host.
  • antigens against and/or specific for rotavirus, respiratory syncytial virus, Mycobacterium tuberculosis, human immunodeficiency virus, E.coli, Vibrio cholera, streptococci and chlamydia are especially preferred for use as an antigen in the vaccines of the invention.
  • the antigen is preferably such that, upon expression, it still allows - at least to some extent, which may be reduced compared to the native strain - the recombinant bacterial host to settle in and/or colonize (part of) the gastrointestinal tract upon administration, and to persist there. This may be for a time sufficient to provide a significant immune response against the antigen and/or the pathogen associated with it.
  • the antigen may be expressed in the bacterial strain using any expression system known per se that expresses the antigen in the recombinant bacterial host in a manner that makes the host suitable for use in the vaccine. This means that at least the antigen should be expressed intracellularly and/or such that it becomes exposed on the surface of the bacterial host, and at a suitable level, e.g. at least 1 - 5 % of total cell protein(as measured by SDS-poiyacrylamide gel electrophoresis and standard protein staining) .
  • the expression system will comprise a genetic construct comprising at least one nucleotide sequence encoding the desired antigen(ic component), preferably operably linked to a promoter capable of directing expression of the sequence in the bacterial host.
  • the antigen to be expressed can be encoded by a nucleic acid sequence that is adapted to the preferred codon usage of the bacterial host .
  • the construct may further contain (all) other suitable element(s) , including enhancers, transcription initiation sequences, signal sequences, reporter genes, transcription termination sequences, etc., operable in the selected bacterial host.
  • the construct is preferably in a form suitable for transformation of the bacterial host and/or in a form that can be stabley maintained in the bacterial host, such as a vector or plasmid. More preferably, a food grade construct is used.
  • a particularly preferred construct according to the invention comprises the multi-copy expression vector described in PCT/NL95/00135 (WO-A-96/32487), in which the nucleotide sequence encoding the antigen has been incorporated.
  • Such a construct is particularly suitable for expression of a desired protein or polypeptide in a lactic acid bacterium, in particular in a Lactobacillus, at a high level of expression, and also can be used advantageously to direct the expressed product to the surface of the bacterial cell.
  • the constructs e.g.
  • PCT/NL95/00135 may be characterised in that the nucleic acid sequence encoding the antigen is preceded by a 5' non-translated nucleic acid sequence comprising at least the minimal sequence required for ribosome recognition and RNA stabilisation. This can be followed by a translation initiation codon which may be (immediately) followed by a fragment of at least 5 codons of the 5' terminal part of the translated nucleic acid sequence of a gene of a lactic acid bacterium or a structural or functional equivalent of the fragment. The fragment may also be controlled by the promoter.
  • the contents of PCT/NL95/00135 including the differing embodiments disclosed therein, and all other documents mentioned in this specification, are incorporated herein by reference.
  • the construct used provides a level of expression - e.g. intracellularly and/or exposed at the surface - that is at least comparable to the level provided by a vector of PCT/NL95/00135 in the same bacterial host under the same conditions.
  • the vaccines of the invention are preferably oral vaccines, that is to say they are adapted for oral administration.
  • Such oral vaccine compositions will usually be alkaline, since usually alkali is required in order to neutralise acid in the stomach, and allow the bacteria (or at least most of them) to pass through the stomach into the intestine alive. It is preferred that most of the bacteria administered will survive the stomach, and pass into the intestine. Increased immune responses can be achievable when the bacteria are alive, that is to say viable, rather than dead. This is because they can continue to express the heterologous antigen in vivo. Not all pharmaceutical formulations will be alkaline, and therefore those that are not alkaline (for example nasal formulations) will not be suitable for oral administration.
  • sequence encoding the antigen can be obtained from any natural source and/or can be prepared synthetically using well known DNA synthesis techniques.
  • sequence encoding the antigen can then (for instance) be incorporated in a suitable expression vector to provide a genetic construct of the invention, which is then used to transform the intended bacterial host strain (for instance as described in PCT/NL95/00135).
  • the recombinant bacterial host thus obtained can then be cultured, upon which the harvested cells can be used to formulate the vaccine, optionally after further purification and/or processing steps, such as freeze-drying to form a powder.
  • the techniques required to create the genetic constructs containing the antigen-encoding sequence and for transforming, culturing and harvesting the bacterial hosts are well known in the art. For instance they are described in PCT/NL95/00135 as well as in standard handbooks, including Sambrook et al, "Molecular Cloning: A Laboratory Manual” (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory (1989) and F.Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987).
  • the vaccine comprising the bacterial host can be formulated in a known manner, such as for the formulation of vaccines and/or for the formulation of preparations of live bacteria for oral administration to an animal or human. Reference can be made to preparations for the administration of probiotics, e.g. for the treatment of gastrointestinal disorders.
  • the vaccine according to the invention can be in a form suitable for oral administration, which may be a solid, semi-solid or liquid form, including but not limited to solutions and/or suspensions of the bacteria, which are usually preferred.
  • the vaccine preparation may also be in the form of a powder, such as a freeze dried powder that can be reconstituted before use, e.g. using a suitable liquid. It may be in the form of a solid or liquid preparation that is (to be) mixed with solid, semi- solid or liquid food prior to administration. It may also be in the form of a fermented product.
  • the vaccine may contain one or more pharmaceutically acceptable carriers or excipients, such as water.
  • the vaccine may also contain one or more adjuvants, including immune adjuvants, suitable for oral administration. These are compatible with the bacterial host and suitably do not interfere (too much) with its desired immunogenic properties.
  • the adjuvants may be a lactic acid bacterium, such as the bacterial host strain itself, one of the other L. plantarum strains mentioned above, another Lactobacillus species, or even a Lactococcus, Bifidobacterium or Propionibacterium species suitable for oral administration to humans or animals.
  • the vaccine may contain one or more further therapeutic substances and/or one or more substances that can facilitate and/or enhance the colonization of (part of) the G.I. tract by the bacteria, and/or the growth of the bacteria in the G.I. tract.
  • the preparation may also be in a form suitable for (direct) administration into the stomach or gut, for instance via a tube or catheter.
  • the bacterial host settles in, and may thereupon colonise, the gastrointestinal tract, or at least a part thereof, such as the mouth, the gut, the small intestine (e.g. duodenum, jejunum or ileum), the large intestine (or part thereof, such as the caecum) or colon, and preferably either the small intestine or the caecum.
  • the antigens expressed by the bacterial host thus can come into contact with the mucosal layer, the lining and/or the wall of the G.I. tract (collectively referred to hereinbelow as "wall of the G.I. tract"), and more specifically with cells within this wall.
  • This can mediate an immune response against the antigen(s) thus presented, such as antigen-presenting cells (for example macrophages, dendritic cells and/or B-lymphocytes).
  • antigen-presenting cells for example macrophages, dendritic cells and/or B-lymphocytes.
  • the tract may by itself already constitute a significant immune response as defined herein, and/or it may trigger further immunological reactions/responses in the body of the human or animal to which the vaccine has been administered, which again may be a significant response and/or may be a protective response as defined herein.
  • the invention is not limited to any specific mechanism via which the recombinant bacterial host elicits any immune response(s).
  • the immune response elicited by an antigen as expressed by the bacterial host may provide a stronger or enhanced immune response compared to the response that would be elicited by the antigen as such, e.g. as a (free) soluble protein.
  • the manner in which the antigens are presented and/or delivered to the wall of the G.I. tract and/or to specific cells therein - such as the cells which mediate and/or are involved in the immune response - may be improved or enhanced when compared to the administration, expression and/or use of the antigen as a free soluble protein.
  • the bacterial host can adhere to the wall of the G.I. tract and can persist in situ for a long(er) period of time
  • it may be that the antigens are presented locally at the wall of the G.I. tract in a large(r) amount, at a high(er) level or concentration, in a more stable or resistant manner and/or for a long(er) period of time. Any of these may thus providing an (enhanced) immune response.
  • the bacterial host - or any part or fragment thereof and/or any further compound(s) produced by it - may interact with the wall of the G.I. tract and/or with specific cells therein such as the cells which mediate and/or are involved in the immune response. This may enable, facilitate or enhance the immune response to the antigens associated with the bacterial host, such as compared to administration, expression and/or use of the antigen as a free, soluble protein.
  • the antigen is preferably expressed by the bacterial host such that the antigen becomes exposed on the cell surface, it is not excluded that - in order to illicit the immune response - the contents of the cells of the bacterial hosts are in situ (i.e. locally at the wall of the G.I. tract) released and/or liberated from the bacterial cell, e.g. by a mechanism which makes the walls of the bacterial cell wall permeable and/or destroys the cells or the bacterial cell wall.
  • the contents of the cells of the bacterial hosts are in situ (i.e. locally at the wall of the G.I. tract) released and/or liberated from the bacterial cell, e.g. by a mechanism which makes the walls of the bacterial cell wall permeable and/or destroys the cells or the bacterial cell wall.
  • the immunogenic response may not be (just) caused/elicited by the intact bacterial host, but by a part, fragment, fraction or compound thereof for example the antigen as such and/or cell fragments or cell fractions comprising the antigen.
  • the vaccines comprises intact, viable and/or live bacteria, vaccines that (e.g. also) contain fragments, fractions, lysates etc., of or derived from the recombinant bacterial host are not excluded.
  • the amount of bacteria administered is not critical, but suitably it is sufficient for the bacteria to settle into and/or colonize (the desired part of) the G.I. tract, and/or to cause a significant immune response.
  • a suitable amount will be at least 10 8 cfu, preferably 10 8 - 10 10 cfu per dose. This may allow a sufficient amount of bacteria to pass into the intestine, if required. Oral administration of doses less than 10 8 cfu may not always give the desired immunogenicity (at least not in a reliable manner), whereas amounts of more than 5xl0 10 cfu, if cumbersome to administer orally, are less preferred.
  • the above amounts of bacteria may correspond, to for instance, 10 6 to 10 8 cfu per kg of body weight of the human or animal.
  • the concentration of bacteria in the vaccine (or other fo ⁇ nulation) may be at least 5xl0 9 /ml, such as at least 10 1 /ml.
  • the formulation may be administered for only up to 2, 3 or 4 days. The bacteria may still be detectable in the individual at least 5 days, 7 days or 9 days after the first or last administration.
  • the individual to be vaccinated is a human or an animal.
  • the human can be an infant, immunocompromised person, elderly person or a normally healthy infant, child or adult.
  • bacterial hosts used are capable of surviving in/passing through the gut in amounts sufficient to colonize the intestine(s). Nevertheless, one can administer the bacteria in or as a coated or encapsulated preparation, for instance in the form of a delayed release composition or an enteric coated composition.
  • Suitable encapsulating compounds include but are not limited to chitosan, maltodextrin, lipids and oligo- and polysaccharides. Encapsulation may also improve the shelf-life of the vaccine.
  • the vaccine may be adjuvant-free but preferably contains one or more adjuvants.
  • strains of other Lactobacillus species which may also prove suitable for use as a bacterial host, for example in vaccines of the invention.
  • the strains useful in the invention preferably have GRAS status and more preferably are food-grade.
  • suitable strains could possibly also be selected from bifidobacteria and the propriobacteria, e.g. from the genus Bifidobacterium and/or the genus Propriobacterium.
  • suitable strains can be selected by the skilled person in the same way as L. lantarum and/or Lactobacillus can be selected.
  • a suitable test for determining/confirming whether a selected strain is suitable as a bacterial host according to the invention is to transform the host with the TTFC carrying vector pLP401 (for surface anchored/surface exposed expression of the TTFC-antigen) and/or the TTFC carrying vector pLP503 (for intracellular expression of the TTFC-antigen), then to administer the recombinant host thus obtained orally to an animal, preferably a mammal (e.g.
  • the selected recombinant host preferably provides higher (i.e. at least 1% higher) titres than L.plantarum NICMB 8826 and/or L.plantarum 80 when transformed with the same vector and administered under the same conditions; and more preferably titres which are at least 10% higher, even more preferably at least 20% higher.
  • the selected recombinant host preferably provides titres which are at least 70%), more preferably at least 90% of the titres provided by L.plantarum 256 transformed with the same vector and administered under the same conditions, and even more preferably titres which are at least equal to the titres provided by
  • L.plantarum 256 transformed with the same vector and administered under the same conditions.
  • the invention additionally relates to a bacterium which has been previously described for use in the vaccines of the invention.
  • the invention additionally relates to expression vectors suitable for intracellular expression, or exposure on the cell surface, for heterologous antigen. This expression will be in a bacterium, such as a Lactobacillus plantarum as previously described.
  • the invention additionally relates to the use of a Lactobacillus (e.g. L. plantarum) bacterium which has been modified to express a heterologous antigen (e.g. intracellularly and/or on the cell surface) for the manufacture of vaccine for an individual to whom the unmodified L. plantarum is foreign.
  • the unmodified L e.g. L. plantarum
  • plantarum is preferably not found in humans (or in human foods), or for example is not present in the G.I. tract or mucosa of a mammal.
  • the bacteria as described herein can be used in the manufacture of vaccine. This vaccine may be adapted for oral administration. Preferably the bacterium will elicit any immune response on administration.
  • the vaccine of the invention can particularly be used for or preventing tetanus .
  • the invention also relates to the administration of the bacterium or vaccine to an individual, such as a human or animal (e.g. a mammal), where that individual (or subject where appropriate) is in need of bacterium or vaccine.
  • an individual such as a human or animal (e.g. a mammal), where that individual (or subject where appropriate) is in need of bacterium or vaccine.
  • the individual may require treatment or prophylaxis or a particular disease, as described above.
  • mice The delivery of antigens to mucosal-associated lymphoid tissues in paediatric and immuno-compromised populations by safe non-invasive vectors, such as commensal lactobacilli, represents a crucial improvement to prevailing vaccination options.
  • safe non-invasive vectors such as commensal lactobacilli
  • the oral and nasal immunisation of mice is described with vaccines constructed for heterologous gene expression in Lactobacillus in which the 50kDa fragment C of tetanus toxin (TTFC) is expressed either as an intracellular or surface- exposed protein.
  • TTFC tetanus toxin
  • the data indicate that the strain Lactobacillus plantarum is more effective than Lactobacillus casei.
  • Immunisation of mice with live recombinant lactobacilli induced significant levels of circulating TTFC-specific IgG following nasal or oral delivery of vaccine strains.
  • slgA in bronchoalveolar lavage fluids as well as antigen-specific antibody-secreting cells and antigen-specific T-cell activation in draining lymph nodes following nasal delivery were induced, substantiating their potential for safe mucosal delivery of paediatric vaccines.
  • Live microbial vaccine-vectors viable at target sites of mucosal immunisation represent efficient delivery systems to facilitate immune responses at mucosal and systemic sites concurrently. Observations to date have underlined the superiority of attenuated pathogenic viruses and bacteria over non-replicating antigens for the induction of mucosal immune responses. Oral subunit vaccine-approaches based upon peptides or purified recombinant proteins may therefore be deficient in this one important requisite, the induction of protective immunity in the G.I.-tract itself. Oral vaccination remains safe and inexpensive whilst maintaining the potential for single- dose immunity, contributing therefore to improved compliance rates in vaccination programs.
  • Tetanus toxin fragment C is the 50kDa non-toxic papain cleavage product of the tetanus holotoxin and is an alternative protective immunogen and is currently utilised in several live-vector systems under development.
  • the delivery of vaccine subunits to the mucosal surfaces by a suitable live microbial vector is a rational response to the obstacles encountered by parenteral vaccines.
  • potential safety and environmental considerations, particularly the immune status of the vaccine recipients in developing countries still negates the employment of the majority of mucosally delivered vector-candidates such as
  • Immune homeostasis at the mucosa, in which lactobacilli participate, is a combination of physical exclusion, IgA secretion and active regulation by T-cell subsets
  • Possibilities were investigated to avoid antigen- specific peripheral tolerance following oral delivery (oral tolerance) by vaccinating with TTFC in particulate form (contrasting soluble dietary antigens), to permit processing and presentation by mechanisms ordinarily contributing to immune regulation of intestinal flora.
  • oral tolerance oral tolerance
  • TTFC in particulate form
  • the data indicate that the strain Lactobacillus plantarum 256 is more effective as compared to Lactobacillus casei 393 and that delivery of TTFC expressed as an intracellular antigen was, in some situations, slightly better than cell-surface expression (under the conditions tested and the detection techniques employed).
  • E. coli DH5 ⁇ was used as a host strain for manipulation of the previously described pLP401 or -503 shuttle vectors(Maassen et al, Vaccine 17: 2117, 1999).
  • the 1329 bp DNA coding for TTFC was elongated at its 3' end with ⁇ JzoI and Ncol restriction sites using PCR techniques, to facilitate cloning into the pLP401 and pLP503 shuttle vectors.
  • p-ldh promoter sequence of ldh gene of L. casei
  • p ⁇ -amy promoter sequence of ⁇ -amylase gene of I. amylovorus
  • Ery r erthromycin resistance gene
  • Amp r ampicillin resistance gene
  • ssAmy sequences encoding secretion signal (36 aa) of ⁇ -amylase gene of L. casei
  • Anchor anchor peptide (117aa) encoding sequences of L. casei
  • TTFC 1329 bp DNA coding for the fragment C of tetanus toxin.
  • Lactobacillus spp. appropriate as host strains for transformation were identified by quantitative cultures of faecal samples obtained following inoculation of mice with single intra-gastric doses of 10 9 cells of a wide panel of rifampicin-resistant wild-type lactobacilli. L. plantarum 256 (P. Conway, Sydney, Australia or Adlerberth et al, Appl & Env. Microbiology, Vol. 62(7): 2244-2251, 1996) which persisted in the G.I. tract for up to 12 days and L. casei (ATCC 393) which became undetectable within 72 hours, were selected as prototype host-strains.
  • Recombinant L. casei and L. plantarum containing the plasmids detailed in Table 1 above were routinely prepared from glycerol stocks by semi-anaerobic overnight (o/n) growth of a 1 :50 dilution in MRS medium containing 5 ⁇ g/ml erythromycin.
  • Transformants with plasmids containing the constitutive ldh promoter were optimally grown in antibiotic selective LCM medium with 2% (w/v) glucose at 37°C.
  • Transformants with plasmids containing the regulatable ⁇ -amy promoter were grown by diluting an o/n culture of cells 1 :50 in mannitol (2% w/v) containing LCM medium.
  • Total cell extracts were obtained from the bacteria by sonicating cells four times on a 30 sec on/30 sec off cycle using a W870 BransonTM sonicator, to release both cytoplasmic or cell membrane-bound proteins.
  • Proteins in 30 ⁇ g of total cell extracts or fractions were separated by SDS- polyacrylamide gel electrophoresis (PAGE), (10% acrylamide, 400mM Tris [pH 8.9]) and run in a 25mM Tris, 192mM glycine buffer (pH 8.3) at 200V for 45 mins. Protein was transferred electrophoretically onto nitrocellulose using a BioradTM electrophoresis unit. Immunoblots were developed using optimally diluted rabbit TTFC-specific antiserum and goat-anti-rabbit IgG-specific phosphatase conjugates (Nordic, Tilburg, The Netherlands).
  • bacteria were prepared for analysis by FACScan.
  • Cells were washed twice and re-suspended in PBS/1% Bovine serum albumin (BSA). 50 ⁇ l of optimally diluted Rabbit TTFC-specific antiserum was added to the cells for 1 hour.
  • Cells were again washed twice and bound antibody was detected by a 30 min incubation with fluorescein isothiocyanate-conjugated (FITC) anti-rabbit at a dilution of 1 : 1000.
  • FITC fluorescein isothiocyanate-conjugated
  • Cells were then washed twice prior to analysis for light scatter and fluorescence on a Becton-Dickinson flow cytometer.
  • a gate was set around appropriate size events as determined by cytograms of forward and side scatter.
  • Controls were prepared by staining wild-type L. casei 393 or L. plantarum 256, staining recombinants using non- immune rabbit serum or excluding the rabbit TTFC-specific antiserum. All procedures were performed on ice with 1% BSA. For each sample data was collected for 10,000 - 20,000 gated events. The fluorescence obtained from bacterial cell suspensions was represented by fluorescence histogram and mean channel intensities calculated.
  • Bacteria obtained from the o/n cultures were diluted 1 :50 in MRS or LCM medium containing 1% glucose and grown for 6 hours at 37°C until an OD695nm of between 0.6 - 0.8 (mid-exponential phase) was reached. Cells were pelleted by centrifugation at 4°C, washed once with PBS and appropriate concentrations of bacteria prepared in sterile PB S .
  • mice For oral immunisation 2-5x10 cells were administered intra-gastrically in a 250 ⁇ l volume of 0.2M NaHCO 3 on three consecutive days. For intra-nasal immunisation 2-5x10 9 cells were administered to the nares of non-anaesthetised mice in 20 ⁇ l volume of PBS. Control mice received identical doses of wild type lactobacilli. Plate counts were performed with all inoculum samples to confirm CFU amounts administered to the mice.
  • Serum was prepared from blood samples obtained from the tail vein from pre- immune mice and subsequently at 7 day intervals beginning 21 days following immunisation.
  • mice were sacrificed at specific time- points and the lungs were canulated and inflated repeatedly with 0.7 ml of PBS/0.1%BSA, following which the collected wash volume was centrifuged at lOOOg and the supernatants stored at -80°C.
  • Antigen-specific immunoglobulin G (IgG) levels were evaluated using microtiter plates coated o/n with 50 ⁇ l of a 0.16 ⁇ g/ml solution of TT (RIVM, Bilthoven, The Netherlands). Individual serum samples were titrated by serial log 2 dilutions and assayed in duplicate. Bound antibody was detected by the addition of 50 ⁇ l of optimally diluted goat anti-mouse IgG-phosphatase conjugate (Nordic, Tilburg, The Netherlands). Following the addition of the PNPP (lmg/ml in 0.1M DEA/ MgCl 2 ) chromogen substrate, antibody levels were quantified by measuring plate A405nm values obtained 30-90 minutes following the initiation of reaction.
  • End-point titres were calculated using a cut-off determined from the mean absorbance (OD 0.2) of a 1 :10 dilution of serum obtained from pre-immune mice.
  • IgA immunoglobulin A
  • broncho-alveolar lavage fluid the same procedure was performed, using an optimally diluted goat anti-mouse IgA phosphatase conjugate (Nordic).
  • Antigen-specific T lymphocyte proliferation assays and ELISPOT.
  • mice spleens and cervical lymph nodes (CLN) of mice were removed aseptically.
  • Single cell suspensions were prepared by passage through a cell strainer (70uM Nylon; B&D, ), and centrifugation at 1500rpm for 10 min. Viable, un-fractionated cell numbers were assessed by Trypan blue dye exclusion.
  • cells were resuspended and plated at concentrations of 3x10 3 cells/spleen or 5x10 5 cells/LN in a final volume of 200 ⁇ l culture medium (RPMI- 1640, supplemented with 10% heat-inactivated fetal calf serum, 2 mM-L-glutamine, 20U/ml penicillin and 20 ⁇ g/ml streptomycine (all Gibco, Pairsley, UK), and 50 ⁇ M 2-mercaptoethanol ⁇ Sigma, MO ⁇ ) in sterile flat-bottomed 96- well culture plates (Nunc, Denmark). Control wells contained medium only, and antigens were added to triplicate cultures over the indicated dose range.
  • RPMI- 1640 supplemented with 10% heat-inactivated fetal calf serum, 2 mM-L-glutamine, 20U/ml penicillin and 20 ⁇ g/ml streptomycine (all Gibco, Pairsley, UK), and 50 ⁇ M 2-mercaptoethanol ⁇ Sigma, MO
  • TT-specific antibody-secreting cells ASC
  • CLN TT-specific antibody-secreting cells
  • PBS/0.1%BSA cells were added at concentrations of lxl 0 6 and 2x10 5 cells/spleen or 5x10 5 and lxlO 5 cells/LN into a final volume of 50 ⁇ l culture medium and incubated for 4h in a humidified 5% CO atmosphere at 37°C.
  • the plates were rinsed and incubated for 20 min. with ice-cold PBS containing lOmM EDTA to remove the cells, and washed again with PBS/0.05% Tween-20, and PBS/0.5% BSA. Bound antibody was detected by the addition of 50 ⁇ l of optimally diluted rabbit anti-mouse Ig phosphatase- conjugate (DAKO, Denmark) o/n at 4 °C. Plates were washed extensively, and incubated with lmg/ml BCIP in AMP buffer containing 1% low melting temperature agarose. The plates were inverted over a light source, and macroscopically blue dots were scored.
  • TTFC-specific rabbit antiserum Expression of cytoplasmic or cell wall bound TTFC by L. plantarum and L. casei transformants was demonstrated by collection of cells in mid-exponential phase followed by sonication to disrupt the bacteria. Proteins were separated by SDS-PAGE and immunoblots developed using TTFC-specific rabbit antiserum.
  • pLP401-TTFC transformants were grown in LCM (+2% mannitol) and pLP503-TTFC transformants (intracellular expression) in MRS (Difco), (both supplemented with 5 ⁇ g/ml erythromycin), at 37°C to an OD 0.6, pelleted and disrupted by sonification. 30 ⁇ g total protein was analysed on a 10% SDS/polyacrylamide gel and separated proteins transferred to nitrocellulose electrophoretically.
  • TTFC was visualised with rabbit anti-TTFC (1 :500) and a phosphatase/PNPP chromogen combination. Bars indicate the migration of molecular weight markers. Immuno-fluorescence analysis was performed of recombinant L.
  • lactobacilli containing pLP503-TTFC express only the intracellular 50kDa TTFC polypeptide.
  • L. plantarum containing the vector pLP401- TTFC express a surface-anchored 75kDa polypeptide corresponding to the 50kDa TTFC fused to an anchor sequence of 25kDa, at a level higher than for L. casei pLP401-TTFC. Exposition of TTFC on the cell-wall of L. plantarum and L. casei through fusion to the anchor sequence was confirmed by FACscan.
  • Serum was collected from pre-immune mice and at 7 day intervals beginning on day 7.
  • TTFC-specific serum IgG in individual or pooled serum was measured by ELISA using microtitre plates coated o/n at 4°C with 0.16 ⁇ g/ml of tetanus toxoid in PBS. Bound antibody was detected by the addition of anti-mouse AP conjugate and PNPP substrate. OD 05n m values of each well were measured at 90 mins. End-point titres were determined using a cut-off value calculated as the mean OD+ 2 SD's ( «0.2) of pre-immune sera diluted 1:10. Table 2 shows the results of the following three protocols. A.
  • mice were immunised intra-nasally with 3 doses of 5x10 9 L. plantarum pLP503-TTFC or 3 doses of 5x10 9 L. casei pLP503-TTFC in 20 ⁇ l of
  • mice 16 C57BL/6 mice were immunised with 3 doses of 5x10 9 L. plantarum pLP503-TTFC intra-nasally in 20 ⁇ l of PBS or orally in 200 ⁇ l of NaHC0 3 on days 1-3. Identical booster immunisations were administered on days 28-30 C. 3 C57BL/6 mice were immunised with 5x10 9 L. plantarum pLP503- TTFC intra-nasally in 20 ⁇ l of PBS on day 1 and day 28 or 3 doses of J. plantarum pLP401-TTFC intra-nasally in 20 ⁇ l of PBS on days 1-3 followed by a booster with either 5x10 9 L. plantarum pLP503-TTFC on days 28-30, or L. plantarum pLP401 -TTFC on days 28-30 and 49-51 , intra-nasally in 20 ⁇ l of
  • mice receiving three i.n. doses of L. plantarum or L. casei expressing intracellular TTFC on days 1-3 were strongly primed for a secondary response to TTFC following booster i.n. administrations on days 28-30.
  • the titre of the TTFC-specific response in BALB/c mice following immunisation with recombinant L. plantarum was higher than recombinant L. casei (Table 2A), with IgG detectable as rapidly as day 28, rising to titres of 10 3'5 and 10 2 by day 49, respectively.
  • Table 2A Titre (Logio) vs days post immunisation
  • intranasal L.plant TTFc mean* 0.0 0.0 1.2 3.5 3.4
  • intranasal L.casei TTFc mean 0.0 0.0 0.3 2.95 2.8
  • mice demonstrated mean end-point titres higher (though not significantly) than BALB/c mice (Table 2B) and therefore were selected for further analysis by i.n. immunisation using a single-dose priming and booster schedule with the L. plantarum transformants that expressed TTFC intracellularly (Table 2C).
  • Table 2B Titre (logio) vs days post immunisation
  • oral L.plant TTFc mean* 0.000 0.100 0.881 1.350 0.986
  • intranasal L.plant TTFc mean* 0.000 1.840 4.275 4.219 4.163
  • Table 2C Titre (logip) vs days post immunisation
  • mice primed as above, with the L. plantarum pLP401-TTFC did induce TTFC-specific serum IgG (with more rapid kinetics than responses obtained from naive mice), when boosted on days 28-30 using the L. plantarum pLP503-TTFC transformant instead (Table 2C).
  • TT-specific IgA in these samples was measured by ELISA using microtitre plates coated o/n at 4°C with 0.16 ⁇ g/ml of tetanus toxoid in PBS. Bound antibody was detected by the addition of anti-mouse AP conjugate and PNPP substrate. OD 05n m values of each well were measured after o/n at 4°C.
  • mice receiving three doses of L. plantarum expressing TTFC on days 1-3 were primed mucosally for a TT- specific IgA response in broncho-alveolar lavage fluids measured on 12 and 21 days following booster i.n. administration on days 28-30.
  • Bronchoalveolar lavages obtained from mice immunised i.n. with wild-type L. plantarum 256 demonstrated no reactivity with TT coated onto microtitre plates at either day 12 or day 21 respectively.
  • Tables 3A, B, C and D OD o 5nm vs days after intranasal (A,B) or oral (C,D) boost
  • mice In contrast to the intra-nasal group, in orally immunised mice no TT-specific IgA response could be measured in bronchoalveolar lavages at either day 12 or day 21 respectively (Table 3 C & D). In an additional study, mice were orally primed on days 1, 2 and 3 and boosted either 2, 3 or 4 weeks later. Irrespective of the timing of the boost, a TTFC-specific IgG response was observed within 7 days of the booster inoculation.
  • mice immunised orally with the L. casei transformants (expressing TTFC either intracellularly or surface-anchored), or L. plantarum expressing TTFC on the cell surface failed to induce detectable TTFC- specific serum IgG responses at all equivalent time points examined.
  • Mice receiving wild-type lactobacilli or irrelevant vectors demonstrated no TTFC-specific serum IgG responses at any time point (data not shown).
  • mice were immunised either orally or intranasally on days 1-3 with either 5x10 9 L. plantarum pLP503-TTFC transformants or the wild-type L. plantarum 256 as control. This was followed by an identical booster immunisation on days 28-30. At 12 days or 21 days following the last boost, mice were sacrificed and spleens and CLN cell suspensions were prepared.
  • Table 4 Enumeration of tetanus -toxoid specific antibody-secreting cells per 10 ,6 cells in spleens and cervical lymph nodes 12 and 21 days after the last boost. 12 days 21 days
  • mice per group were immunised at days 1-3 intra-nasally (i.n.) or orally with 5x10 9 L. plantarum (either L. plantarum 256 or L plantarum pLP503-TTFC transformants), followed by an identical booster immunisation at days 28-30. 12 Days or 21 days after the last boost per group 8 animals were sacrified and spleens and cervical lymph nodes (CLN; pooled per 2 animals) cell suspension were prepared. The amount of TT-specific Ig producing cells were determined by ELISPOT. #The data, presented as antibody-secreting cells (ASC) per 10 6 cells, represent the mean (range) of 8 spleens samples or 4 CLN samples, measured in triplicate wells.
  • ASC antibody-secreting cells
  • TT-specific antibody secreting cells ASC
  • ELISPOT TT-specific antibody secreting cells
  • mice were immunised at days 1-3 intra-nasally (i.n.) or orally with 5x10 9 L. plantarum (either L. plantarum 256 or L plantarum pLP503-TTFC transformants), followed by an identical booster immunisation at days 28-30. 12 Days (A & C) or 21 days (B & D) after the last boost per group 8 animals were sacrificed and spleens (A & B) and CLN (pooled per 2 animals)(C & D) cell suspension were prepared.
  • the cells were examined for [ 3 H] thymidine incorporation following in vitro incubation of 3xl0 5 spleen cells or 5xl0 5 CLN cells per well for 72 hours with TTFC, TT, TT peptide P30 or medium alone. [ H] thymidine was added to the cultures in the last 18 hours. Results are expressed as the SI calculated from the mean cpm of triplicate test cultures of cells divided by the mean cpm of cultures receiving buffer alone. The background values of cultures receiving buffer alone varied from: A 220-760 cpm, B: 150-240 cpm, C 1000-4000 cpm, and D 150-560 cpm.
  • FIG. 1 the antigen-specific T-cell responses of spleen or CLN are presented.
  • proliferation is measurable following re-stimulation with either TTFC, TT or TT peptide P30, suggesting that i.n. immunisation induced specific immunity initially via local lymph node activation.
  • Antigen-specific T cell responses of spleen and CLN were also obtained in BALB/c mice. No antigen-specific proliferation was observed in cells obtained from mice immunised orally or identical routes with wild- type L. plantarum (Fig.l).
  • the pLP401- /503- plasmids enabled directed (-surface or intracellular) and regulatable expression of TTFC at levels and efficiencies not previously attainable in Lactobacillus.
  • the L. plantarum pLP503-TTFC that expressed TTFC intracellularly was demonstrated to be very immunogenic following intranasal delivery, priming on days 1-3, and boosting at days 28-30. Immunogenicity was shown at the systemic level by high TT-specific IgG serum titres, as well as at the mucosal level, showing TT-specific IgA in the BAL fluids.
  • TT-specific ASC and antigen-specific T-cell proliferation were demonstrated at the systemic level in spleens as well as locally in cervical LN.
  • L. plantarum-p F503-TTFC moderate titres of TT-specific serum IgG were measured.
  • the L. casei and L. plantarum strains were sampled efficiently by the M-like cells found in the nasal tracts and induced substantial levels of immunoglobulins in serum.
  • the variations in both the levels of TTFC expression, sustainable levels of non- degraded TTFC and the persistence in the G.I. -tract between the recombinant strains may have pivotal influences on the potency of the recombinant vaccine and may account for the often surprising observations distinguishing the L. plantarum and L. casei strains.
  • the L. plantarum pLP401-TTFC recombinant strains expressing relatively low levels of surface-exposed TTFC, were immunogenic following i.n. administration, though it was necessary to both prime mice (on days 1-3) and subsequently boost twice (on days 28-30 and 49-51) before antigen-specific responses were measurable.
  • mice primed as above, with the L. plantarum pLP401-TTFC did induce TTFC-specific serum IgG (with more rapid kinetics than responses obtained from naive mice), when boosted as early as days 28-30 using the L. plantarum pLP503-TTFC transformant instead. This observation implies that antigen-specific sensitisation of the mice has in fact occurred following administration of L.
  • the present study provides a significant endorsement for Lactobacillus-based vaccines by extending the observations of immunogenicity following nasal immunisation to demonstrate for the first time that oral immunisation of C57BL/6 mice with 5x10 9 L. plantarum expressing TTFC intracellularly induces TTFC-specific serum IgG responses.
  • L. casei and L. plantarum were selected for study due to their different periods of persistence in the G.I. tract. The differences in persistence may explain the differences found in immunogenicity.
  • the antigen may be expressed at lower amounts at the cell surface than intracellularly (almost a difference of an order of magnitude) and so there may be a dosage effect.
  • the cell surface proteins are more susceptible to proteolysis.
  • the protein may have had a slightly different conformation on the cell surface from the equivalent intracellular protein, and furthermore such antigens on the cell surface may change activities at the cell surface, for example with regard to adherence.
  • the antigen delivery vehicles described emphasise the need to define host- vector combinations and evaluate the impact cell viability, cell numbers, adhesion to the mucosa and the mechanism of triggering of the immune system has on the immunogenicity of the recombinant lactobacilli.
  • This first demonstration of TTFC immunogenicity following delivery of recombinant lactobacilli by the oral route has endorsed safe Lactobacillus-based oral neonatal vaccines to combat, for example, the current 400,000 deaths due to tetanus recorded annually.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de bactéries Lactobacillus recombinées ou modifiées dans des vaccins. Ces bactéries expriment un antigène hétérologue, soit de manière intracellulaire, soit à la surface de la bactérie, et provoquent ainsi une réponse immunitaire. Ces vaccins conviennent pour une administration par voie orale. Les bactéries préférées sont celles de l'espèce Lactobacillus plantarum, en particulier L. plantarum 256.
EP00962689A 1999-09-17 2000-09-18 Vaccins oraux a base de lactobacilles recombinees Withdrawn EP1212083A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00962689A EP1212083A1 (fr) 1999-09-17 2000-09-18 Vaccins oraux a base de lactobacilles recombinees

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99203056 1999-09-17
EP99203056A EP1084709A1 (fr) 1999-09-17 1999-09-17 Vaccin oral contenant des Lactobacilli recombinés
EP00962689A EP1212083A1 (fr) 1999-09-17 2000-09-18 Vaccins oraux a base de lactobacilles recombinees
PCT/GB2000/003575 WO2001021200A1 (fr) 1999-09-17 2000-09-18 Vaccins oraux a base de lactobacilles recombinees

Publications (1)

Publication Number Publication Date
EP1212083A1 true EP1212083A1 (fr) 2002-06-12

Family

ID=8240652

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99203056A Withdrawn EP1084709A1 (fr) 1999-09-17 1999-09-17 Vaccin oral contenant des Lactobacilli recombinés
EP00962689A Withdrawn EP1212083A1 (fr) 1999-09-17 2000-09-18 Vaccins oraux a base de lactobacilles recombinees

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99203056A Withdrawn EP1084709A1 (fr) 1999-09-17 1999-09-17 Vaccin oral contenant des Lactobacilli recombinés

Country Status (10)

Country Link
EP (2) EP1084709A1 (fr)
JP (1) JP2003509469A (fr)
CN (1) CN1387442A (fr)
AP (1) AP2002002445A0 (fr)
AU (1) AU7433700A (fr)
CA (1) CA2383433A1 (fr)
IL (1) IL148713A0 (fr)
OA (1) OA12023A (fr)
WO (1) WO2001021200A1 (fr)
ZA (1) ZA200201969B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1739178T3 (da) * 1999-07-05 2010-11-22 Actogenix Nv Levering af trekløverpeptider
US7060687B2 (en) 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
JP4059648B2 (ja) * 2001-08-28 2008-03-12 独立行政法人科学技術振興機構 経口用サイトカイン誘導剤
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
EP1319410A1 (fr) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Utilisation de microorganismes pour l'administration ciblée de substances dans des parties spécifiques de l'intestin
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
EP1523559A1 (fr) * 2002-06-18 2005-04-20 Universite Catholique De Louvain Mutants de paroi cellulaire pour la delivrance de composes biologiquement actifs
DE602004005029T2 (de) * 2003-05-22 2007-11-08 Synbiotics Ab Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen
EP1680508B1 (fr) * 2003-10-28 2011-03-30 Friesland Brands B.V. Production et/ou administration intestinale specifique de site de substances actives
EP1768688A4 (fr) * 2004-07-02 2009-09-30 Raymond J Dattwyler Vaccin oral permettant de lutter contre des infections a borrelia
EP1723965A1 (fr) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions pour l'induction de tolerance immunologique specifique à des antigènes à travers de la immunization orale
WO2006126682A1 (fr) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccin pour la prévention / le traitement de la maladie d'alzheimer
US8420376B2 (en) * 2005-10-06 2013-04-16 Probi Ab Use of Lactobacillus for treatment of virus infections
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP5791009B2 (ja) * 2008-12-22 2015-10-07 アサヒグループホールディングス株式会社 乳酸菌およびそれらを用いた飲食物又は化粧品
CN103732248B (zh) * 2011-04-06 2018-08-28 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
BR112013025481B8 (pt) 2011-04-06 2022-11-22 Univ Paris Descartes Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos
CN102580118B (zh) * 2012-02-24 2014-03-12 重庆大学 志贺样毒素Stx1B口服疫苗的制备方法及其产品
WO2014047625A1 (fr) * 2012-09-24 2014-03-27 Montana State University Lactococcus lactis recombinant exprimant l'antigène 1 du facteur de colonisation d'escherichia coli (cfa/i) de type pilus et procédés d'utilisation correspondants
KR102143856B1 (ko) * 2013-06-11 2020-08-12 하우스 웰니스 푸드 코퍼레이션 대식세포에 물질을 송달하는 담체
SG11202009631WA (en) 2018-03-31 2020-10-29 Pebble Labs Usa Inc Systems, methods and composition of using rnase iii mutants to produce srna to control host pathogen infection
CA3198308A1 (fr) * 2020-11-10 2022-05-19 Dharanesh Mahimapura GANGAIAH Compositions probiotiques immunogenes et procedes d'utilisation, y compris a des fins de vaccination
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
CN113308396B (zh) * 2021-05-18 2023-03-21 上海市公共卫生临床中心 一种植物乳杆菌及在制备新冠疫苗免疫增强剂中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗
CN114561313B (zh) * 2021-08-26 2022-09-13 佛山市孛特碧欧微生物科技有限公司 格氏乳杆菌及其应用
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
DE102022119024A1 (de) * 2022-07-28 2024-02-08 INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung Neuartige genetische Werkzeuge
CN117586935B (zh) * 2023-12-01 2024-05-10 华中农业大学 用于产肠毒素大肠杆菌k99菌毛型的乳酸乳球菌载体口服疫苗及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8700890A (nl) * 1987-04-15 1988-11-01 Tno Transformatie van lactobacillus, daarbij bruikbare recombinante plasmiden, getransformeerde lactobacillus species en gebruik daarvan.
GB9718616D0 (en) * 1997-09-02 1997-11-05 Queen Mary & Westfield College Oral vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0121200A1 *

Also Published As

Publication number Publication date
OA12023A (en) 2006-04-19
AP2002002445A0 (en) 2002-03-31
IL148713A0 (en) 2002-09-12
JP2003509469A (ja) 2003-03-11
CA2383433A1 (fr) 2001-03-29
CN1387442A (zh) 2002-12-25
AU7433700A (en) 2001-04-24
EP1084709A1 (fr) 2001-03-21
WO2001021200A1 (fr) 2001-03-29
ZA200201969B (en) 2003-08-27
EP1084709A9 (fr) 2001-05-16

Similar Documents

Publication Publication Date Title
WO2001021200A1 (fr) Vaccins oraux a base de lactobacilles recombinees
Shaw et al. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C‐expressing lactobacilli
Kajikawa et al. Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis
Mercenier et al. Lactic acid bacteria as live vaccines
Grangette et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum
Oliveira et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A
Amdekar et al. Probiotics: multifarious oral vaccine against infectious traumas
Wen et al. Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli
Mohamadzadeh et al. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria
US20130287810A1 (en) Vaccine compositions and uses thereof
CN108779482B (zh) 工程化肠道共生细菌在其外膜囊泡(omv)中表达异源蛋白质以递送至胃肠道
Alimolaei et al. Oral immunization of mice against Clostridium perfringens epsilon toxin with a Lactobacillus casei vector vaccine expressing epsilon toxoid
Kajikawa et al. Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface
Mercenier et al. Edible genetically modified microorganisms and plants for improved health
WO2003063785A2 (fr) Methodes et compositions permettant de distribuer des acides nucleiques et/ou des proteines a la muqueuse intestinale
Mohammadi et al. High protection of mice against Brucella abortus by oral immunization with recombinant probiotic Lactobacillus casei vector vaccine, expressing the outer membrane protein OMP19 of Brucella species
Yang et al. Alleviation of enterotoxigenic Escherichia coli challenge by recombinant Lactobacillus plantarum expressing a FaeG-and DC-targeting peptide fusion protein
JP2005528085A (ja) 修飾された細菌表層タンパク質
CN117202927A (zh) 组合物和方法
EP1490473A1 (fr) Spores bacteriennes
Medaglini et al. Recombinant Gram-positive bacteria as vehicles of vaccine antigens
US20040009937A1 (en) Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20050075298A1 (en) Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
Mohamadzadeh Induction of protective immunity against microbial challenge by targeting antigens expressed by probiotic bacteria to mucosal dendritic cells
Manohar et al. Enhancement of live vaccines by co-delivery of immune modulating proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060814